Boule Diagnostics – Nomination Committee for the Annual General Meeting 2025
The 2024 Annual General Meeting of Boule Diagnostics AB (publ), (“Boule”), resolved that a Nomination Committee based on the ownership structure on 30 September 2024 shall be appointed to propose the Annual General Meeting 2025:
- proposal for Chairman of the Annual General Meeting,
- proposal for the Board of Directors,
- proposal for Chairman of the Board of Directors,
- proposals for fees and other remuneration for Board assignments to each of the Board members and remuneration for committee work,
- proposal for auditor,
- proposal for fees to the Company’s auditor,
- proposals for changes to the principles for the appointment of the Nomination Committee and instructions for the Nomination Committee, to the extent deemed necessary, and
- other matters that are the responsibility of the Nomination Committee in accordance with the Swedish Corporate Governance Code
Boule’s largest shareholders at the above time were AB Grenspecialisten, Svolder AB and Thomas Eklund, representing 34 percent of the share capital and votes. These shareholders have in turn nominated Tomas Risbecker (Svolder AB), Erik Ivarsson (AB Grenspecialisten) and Thomas Eklund. The Nomination Committee has subsequently constituted itself and elected Erik Ivarsson as its Chairman and the Chairman of the Board, Torben Jörgensen has been co-opted to the Nomination Committee.
Shareholders who wish to contact the Nomination Committee are welcome to contact the Chairman of the Nomination Committee Erik Ivarsson via e-mail at erik.ivarsson@grenspecialisten.com. To ensure that proposals will have enough time to be evaluated properly, proposals should be submitted no later than 1 February 2025.
For more information, please contact:
Torben Nielsen, CEO and Group President, Boule Diagnostics AB, torben.nielsen@boule.com
Holger Lembrér, CFO, Boule Diagnostics AB, holger.lembrer@boule.com , phone +46 (0)72-230 77 10
About Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 571 million in 2023 and has more than 200 employees. Sales are conducted globally, predominantly through the company’s 200 or so distributors in over 100 countries, supported by Boule’s own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com
